Navigation Links
PolyRemedy Hires Gary Coughlen as CFO
Date:10/28/2008

approval. In addition, he oversaw many legal functions, including patent filing and protection, and established internal departments and policies.

Prior to Refractec, Coughlen served in financial leadership roles at Scieran Technologies, Inc., Laguna Hills, Calif., Precision Capital, Walnut Creek, Calif., and Sierra Capital, Inc., San Francisco. Coughlen also worked in various positions at Concord Assets Group, Boca Raton, Fla., and Security Properties, Inc., and Pricerwaterhouse, both in Seattle, Wash.

Coughlen holds a bachelor's degree in business/accounting from the University of Washington and an MBA from University of California, Berkeley. He is also a certified public accountant.

About PolyRemedy

PolyRemedy, based in Mountain View, Calif., manufactures robotic systems for the fabrication of nano- and micro-fiber wound treatments, on demand and at the point of care. The innovative PolyRemedy system produces customized wound dressings within minutes, measured to fit the wound size and shape and fabricated with the precise material composition necessary to optimally treat the wound. The system also captures and monitors important wound treatment data with the potential to help evaluate costs, refine clinical protocols, and demonstrate evidence-based improvements in wound management.


'/>"/>
SOURCE PolyRemedy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. PolyRemedy Strengthens Executive Team With Additions of Diane Cooper, PhD, and Joe Coyne
2. Pioneer Surgical Technology Hires Vice President of New Business Development
3. WeissComm Partners Makes 10 New Hires as It Wins New Accounts and Grows Existing Business
4. LehmanMillet Continues Expansion with Strategic Hires
5. AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business
6. Staffing Agency Hires Local Television News Team, Launches Broadband Network for Nurses
7. Medi-Promotions Hires Industry Executive to Expand its Medi-Scripts Prescription Pad Model
8. Pioneer Surgical Technology Hires New Spinal Franchise Manager
9. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
10. FBR Capital Markets Hires Senior Healthcare Analyst
11. Casey Family Programs Hires Ken Patterson as Managing Director of Child and Family Services
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 3Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 4Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 5Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 6Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 7Health News:Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione 2Health News:Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione 3Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Scientific Publications Strategy & Delivery Shifts from Marketing to Medical 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 3Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 4
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 1Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 2DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures 2